Praed is a “start in the middle” biopharmaceuticals company founded by industry experts with more than 60 years of combined experience in the pharmaceutical industry. Our goal is to deliver a next generation treatment for Crohn’s disease. We are a company with a clinical Phase II ready compound, which has a fully established CMC (Chemistry, Manufacturing and Control) and safety profile from a Phase III program encompassing 684 patients in another gastro-intestinal indication.
Praed brings together very experienced Pharma executives with a diverse range of backgrounds from the bench to the bedside of other successful pharmaceutical products. The founder team consists of the 3 former key Actelion employees: Peter Seiler (previously R&D Actelion), Marian Borovsky (previously Group General Counsel Actelion) and Etienne Bucher (previously General Manager Actelion). Together with Joerg Felix (previously Head of Tax Actelion), they form the Executive Board of Directors of Praed.